The Application and Pathway Regulation of Traditional Chinese Medicine in Lung Cancer Treatment: An Exploratory Review DOI Open Access

Jinghan Huang

Qeios, Journal Year: 2024, Volume and Issue: 6(5)

Published: May 30, 2024

Lung cancer is one of the cancers with highest mortality rates. Non-small cell lung (NSCLC) accounts for 85% cases and often diagnosed at an advanced stage a poor prognosis. Due to lack effective molecular targets, current clinical cure rate low, recurrence high. Recent studies have found that active components traditional Chinese medicine herbal formulas can inhibit development NSCLC through multiple pathways effectively reducing its metastasis rates, improving treatment side effects, compensating deficiencies in drug resistance. Although treatments such as surgery, radiotherapy, targeted therapy, immunotherapy achieved better efficacy treating cancer, they still problems complications severe adverse reactions. In recent years, numerous basic confirmed good effects cancer. Traditional has synergistic regulatory effect components, pathways, channels. The monomeric complex mechanisms action determine there are issues unclear related prevention by medicine. There urgent need elucidate intervening from perspective modern medicine, levels biology, network pharmacology, etc. This article systematically summarizes research progress on regulation above-mentioned signaling expression key protein molecules monomers or formulas, aiming clarify progression provide ideas theoretical basis in-depth study application

Language: Английский

Efficacy and Safety Assessment of Intrathoracic Perfusion Chemotherapy Combined with immunological factor Interleukin-2 in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study DOI Creative Commons
Qiang Cao, Jinyi Zhu, Xinyan Wu

et al.

Journal of Cancer, Journal Year: 2024, Volume and Issue: 15(7), P. 2024 - 2032

Published: Jan. 1, 2024

Objective: This study evaluated the efficacy and safety of gemcitabine oxaliplatin intrathoracic perfusion chemotherapy (IPCGOR) regimen combined with interleukin-2 (IL-2) for advanced non-small cell lung cancer (NSCLC).Methods: We conducted a retrospective analysis 460 NSCLC patients from Yunnan Province Early Cancer Diagnosis Treatment Project (June 2020-October 2022), assessing IPCGOR IL-2 combination.Outcomes were measured based on RECIST 1.1 criteria, focusing objective response rate (ORR), disease control (DCR), median progression-free survival (mPFS), overall (MOS), treatment safety.Results: The demonstrated an ORR 67.4%, DCR 97.4%, mPFS 8.5 months, MOS 12.5 months.14 underwent successful surgery post-treatment.Common adverse reactions manageable, no treatment-related deaths reported. Conclusion:The shows promising tolerable profile NSCLC.These findings suggest its potential as reference treating NSCLC.However, study's nature single-center design pose limitations.Future research should focus prospective studies, randomized controlled trials, long-term outcome assessments, particularly in diverse patient subgroups, to further validate refine clinical application this regimen.

Language: Английский

Citations

17
Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients DOI Open Access
Elena Chatzikalil, Kleoniki Roka, Panagiotis Diamantopoulos

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(7), P. 2046 - 2046

Published: April 1, 2024

Over the past two decades, prognosis in adolescents and young adults (AYAs) diagnosed with acute myeloid leukemia (AML) has significantly improved. The standard intensive cytotoxic treatment approach for AYAs AML, consisting of induction chemotherapy anthracycline/cytarabine combination followed by consolidation or stem cell transplantation, lately been shifting toward novel targeted therapies, mostly fields clinical trials. One most recent advances treating AML is B-cell lymphoma 2 (Bcl-2) inhibitor venetoclax hypomethylating agents, which studied elderly populations was approved Food Drug Administration (FDA) patients over 75 years age excluded from schemas due to comorbidities. Regarding AYA population, therapy could be a therapeutic option refractory/relapsed (R/R) although data real-world studies are currently limited. Venetoclax frequently used advanced hematologic malignancies, mainly lymphoblastic myelodysplastic syndromes, as salvage considerable efficacy safety. Herein, we aim summarize evidence obtained trials observational on use AML. Based available evidence, safe effective R/R patients. However, further research larger cohorts needed confirm these data, establishing benefits venetoclax-based regimen this special population.

Language: Английский

Citations

5
Metabolic vulnerabilities in cancer: A new therapeutic strategy DOI
Mohamed El‐Tanani, Syed Arman Rabbani,

Yahia El‐Tanani

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: 201, P. 104438 - 104438

Published: July 6, 2024

Language: Английский

Citations

5
Human platelet lysate: a potential therapeutic for intracerebral hemorrhage DOI Creative Commons

Dachang Qiu,

Lin Wang, Lanlan Wang

et al.

Frontiers in Neuroscience, Journal Year: 2025, Volume and Issue: 18

Published: Jan. 15, 2025

Intracerebral hemorrhage (ICH) is a major public health challenge worldwide, and associated with elevated rates of mortality, disability, morbidity, especially in low- middle-income nations. However, our knowledge the detailed molecular processes involved ICH remains insufficient, particularly those secondary injury stage, resulting lack effective treatments for ICH. Human platelet lysates (HPL) are abundant bioactive factors, numerous studies have demonstrated their beneficial effects on neurological diseases, including anti-neuroinflammatory ability, anti-oxidant effects, maintenance blood-brain barrier integrity, promotion neurogenesis. In this review, we thoroughly explore potential HPL treating from three critical perspectives: rationale selecting as treatment ICH, mechanisms through which contributes to management, additional measures necessary We elucidate role platelets pathophysiology highlight limitations current options advancements preclinical research application disorders. Furthermore, historical developments preparation methods field biomedicine discussed. Additionally, summarize molecules present therapeutic Finally, outline issues that must be addressed regarding utilizing modality

Language: Английский

Citations

0
Development Trends in the Clinical Test of Multiple Myeloma from 2000 to 2023: A Bibliometric Study DOI Creative Commons
Hongcheng Wu,

Haomiao Sun,

Yichen Wang

et al.

Published: Jan. 9, 2025

Objective: This study investigates the development trends and research hotspots in clinical testing for multiple myeloma from 2000 to 2023, using bibliometric techniques. Method: Search relevant literature on of published Web Science Core Collection (WoSCC) use CiteSpace 6.2.R4 software draw a visual knowledge map authors, institutions, national regional cooperation networks, journals, keywords, conduct analysis. Results: The found an upward trend publications over specified period, with significant growth noted 2012 onwards. majority originates United States, contributions institutions like Mayo Clinic MD Anderson Cancer Center. Analysis author collaboration networks indicated relatively low centrality, suggesting minimal among researchers. Bibliometric mapping highlighted several field including therapeutic strategies involving proteasome inhibitors immunomodulatory drugs, role stem cell transplantation, importance achieving monitoring residual disease. Conclusion: is characterized by growing body research, States. Despite increasing volume there need enhanced researchers consolidate findings advance practice.

Language: Английский

Citations

0
BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies DOI Creative Commons

Mariam Markouli,

Maria Pagoni, Panagiotis Diamantopoulos

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 14

Published: Jan. 21, 2025

Apoptosis is an essential characteristic of cancer and its dysregular promotes tumor growth, clonal evolution, treatment resistance. B-cell lymphoma-2 (BCL-2) protein family members are key to the intrinsic, mitochondrial apoptotic pathway. The inhibition BCL-2 pro-survival proteins, which frequently overexpressed in malignancies pose a fundamental carcinogenic mechanism has been proposed as promising therapeutic option, with venetoclax (ABT-199) being first FDA-approved inhibitor. Unfortunately, although shown remarkable results range lymphoid cancers well acute myeloid leukemia (AML), development resistance significantly reduces response rates specific subtypes. In this article, we explain role proteins apoptosis their action that justifies potential target malignancies, including chronic lymphocytic leukemia, multiple myeloma, lymphomas, but also AML. We further analyze characteristics result intrinsic or inherited inhibitors. Finally, focus on biomarkers can be used predict responses name personalized medicine, goal exploring alternative strategies overcome

Language: Английский

Citations

0
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options DOI
Susanna Kim, Adam ElSayed,

Jonathan E. Moore

et al.

Targeted Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 29, 2025

Language: Английский

Citations

0
Knowledge map of programmed cell death in esophageal cancer: a bibliometric analysis DOI Creative Commons

Rulin Li,

Yanchun Yang,

Yang Gao

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: April 24, 2025

This study aimed to delineate the evolving knowledge structure of programmed cell death in esophageal cancer and identify key thematic trends, influential collaborations, emerging areas for future research. A bibliometric approach was applied 2677 publications retrieved from Web Science Core Collection (2000-2024). Three complementary tools-CiteSpace, VOSviewer, bibliometrix-were employed visualize co-citation networks, detect citation bursts, map collaborative patterns among authors, institutions, countries. Inclusion criteria focused on articles reviews that addressed conjunction with apoptosis, necroptosis, pyroptosis, ferroptosis, autophagy, or related pathways. Publication outputs grew markedly, reflecting a shift early investigations basic apoptotic mechanisms broader explorations ferroptosis. China led publication volume citations, driven by substantial governmental funding large clinical cohorts. The United States Japan also contributed significantly, forming international research networks spanned Asia Europe. Leading particularly Zhengzhou University, demonstrated extensive collaborations. Journals such as Oncology Letters Reports were prominent outlets new findings, while highly cited references highlighted hypoxia, immune checkpoint blockade, gene-editing strategies. Keyword analyses revealed ascendance immuno-oncology, network pharmacology, translational applications targeting multiple regulated Bibliometric evidence underscores rapid expansion multidisciplinary integrates diverse pathways cancer. Continued leveraging advanced genomics immunologic strategies, are poised accelerate breakthroughs enable more personalized, effective therapies.

Language: Английский

Citations

0
The Interplay between Autophagy and Mitochondria in Cancer DOI Open Access
Aleksandra Zdanowicz, Emilia Grosicka-Maciąg

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(17), P. 9143 - 9143

Published: Aug. 23, 2024

Besides producing cellular energy, mitochondria are crucial in controlling oxidative stress and modulating metabolism, particularly under stressful conditions. A key aspect of this regulatory role involves the recycling process autophagy, which helps to sustain energy homeostasis. Autophagy, a lysosome-dependent degradation pathway, plays fundamental maintaining homeostasis by degrading damaged organelles misfolded proteins. In context tumor formation, autophagy significantly influences cancer metabolism chemotherapy resistance, contributing both suppression surveillance. This review focuses on relationship between specifically progression. Investigating interaction reveals new possibilities for treatments may result development more effective therapies targeting mitochondria, could have significant implications treatment. Additionally, highlights increasing understanding autophagy’s development, with focus mitochondrial function pre-clinical clinical research. It also explores potential developing more-targeted personalized investigating autophagy-related biomarkers.

Language: Английский

Citations

2
Review of: "The Application and Pathway Regulation of Traditional Chinese Medicine in Lung Cancer Treatment: An Exploratory Review" DOI Creative Commons
Palmiro Poltronieri

Published: March 8, 2024

Language: Английский

Citations

1